• AO/PI Staining Solution for Better Cell Counts

  2026-09-11

  AO/PI Staining Solution strengthens fluorescence-based cell counting in diabetic nephropathy research by separating membrane-intact and compromised cells. This article connects assay quality control with the inflammatory and apoptotic findings reported for phillygenin-treated podocytes and diabetic mice.

• Y-27632: Practical ROCK Inhibitor Workflow

  2026-09-10

  Y-27632 provides a reversible, ATP-competitive way to perturb ROCK1 and ROCK2 activity in biochemical and cell-based assays, supporting controlled studies of cytoskeletal organization and ROCK signaling. It should be used as a research reagent with assay-specific controls, not as evidence of clinical efficacy or as a substitute for independent pathway validation.

• GSK J4 HCl: Testing H3K27 Control of CXCL10

  2026-09-10

  GSK J4 HCl provides a mechanistic way to test how JMJD3-dependent H3K27 demethylation influences inflammatory transcription. This article translates decidual CXCL10 findings into a rigorous, promoter-aware assay strategy while clarifying the compound’s strengths and limitations.

• AO/PI Staining Solution for Mechanistic Cell Counting

  2026-09-09

  Learn how AO/PI Staining Solution strengthens fluorescence-based cell counting in diabetic nephropathy research by separating viability measurement from pathway interpretation. This mechanistic workflow connects live/dead cell discrimination with inflammation, apoptosis, and assay-quality decisions.

• From T7 Transcription to RNA Mechanism in CRC

  2026-09-09

  A translational perspective on how T7 RNA Polymerase can turn mechanistic findings about the DDX21–SIRT7–NAT10 axis into controlled RNA substrates, reproducible assays, and better decisions in colorectal cancer research.

• Intranasal Sumatriptan in Pediatric ED Migraine

  2026-09-08

  A single-center retrospective study evaluated an emergency-department migraine pathway that placed intranasal sumatriptan early in treatment for children and adolescents. The pathway was associated with substantial pain-score improvement, while intravenous access correlated with longer stays and higher charges, supporting further comparative studies rather than proving superiority.

• NMDAR–Cav2.1 Control of PV Interneuron Maturation

  2026-09-08

  Singh and colleagues show that developmental NMDAR signaling in prospective cortical parvalbumin interneurons is required for the maturation of Cav2.1-dependent GABA release, not only for intrinsic excitability. The study links early NMDAR hypofunction to impaired fast-spiking inhibition and provides a mechanistic framework for interpreting schizophrenia-related changes in cortical excitation–inhibition balance.

• AZD1480: A Strategic JAK2/STAT3 Probe

  2026-09-07

  AZD1480 gives translational researchers a focused way to test whether tumor-intrinsic JAK2/STAT3 activation limits the benefit of IDO1 inhibition. This article connects recent immunometabolic findings with practical pathway-validation workflows, biomarker strategy, and combination-study design.

• Acetylcholine Chloride: From Signal to Circuit

  2026-09-07

  Explore how Acetylcholine Chloride can distinguish direct receptor activation from gut–vagus–brain circuit effects. This research-focused guide translates recent microbiota–seizure findings into better temporal, spatial, and mechanistic assay decisions.

• LY294002 Workflows for PI3K/Akt/mTOR Research

  2026-09-05

  Build reproducible PI3K/Akt/mTOR perturbation experiments with LY294002 across cancer, autophagy, and immune-cell models. This guide connects dose-controlled pathway inhibition with the macrophage and airway-inflammation framework reported in recent allergic-asthma research.

• Bradykinin in Vascular Assay Workflows

  2026-09-04

  Bradykinin enables controlled studies of endothelial relaxation, vascular permeability, smooth muscle behavior, pain signaling, and inflammation. This workflow-focused guide shows how to convert a research peptide into reproducible concentration-response, barrier, and tissue assays while avoiding common handling and interpretation errors.

• HATU: From Coupling Chemistry to Assay Design

  2026-09-04

  HATU enables efficient carboxylic acid activation for peptide synthesis chemistry and medicinal chemistry. This guide connects its reaction mechanism with inhibitor design, assay selection, and evidence-based workflow decisions.

• AO/PI Staining Solution for Assay Decisions

  2026-09-03

  AO/PI Staining Solution enables fluorescence-based cell counting by separating membrane-intact and membrane-compromised cells. This guide shows how to use the readout responsibly in diabetic nephropathy research without confusing viability data with mechanistic evidence.

• CHK1 Inhibition in ER/PR-Defined Breast Cancer

  2026-09-03

  This study shows that CHK1 inhibition has context-dependent effects in breast cancer, shaped by oestrogen-receptor and progesterone-receptor status. The findings support biomarker-guided use of CHK1-targeted therapy: inhibition enhanced doxorubicin sensitivity in triple-negative models but produced single-agent activity, rather than chemosensitization, in ER+/PR+/HER2− disease.

• High-Dose Bifendate and Acute Hypertriglyceridemia

  2026-09-02

  A 2006 animal study showed that high oral doses of bifendate sharply increased serum and hepatic triglycerides in rabbits and mice, despite modest reductions in total cholesterol. Its key contribution was establishing a reproducible, dose- and time-sensitive model of acute hypertriglyceridemia and demonstrating that fenofibrate, but not inositol nicotinate, could reverse the response.

8534 records 2/569 page Previous Next 12345 下5页 Last page